FDA Approves Revolutionary Pill for Pancreatic Cancer
· Telemundo McAllen (KTLM)
The U.S. Food and Drug Administration (FDA) has approved a groundbreaking pill for the most common form of pancreatic cancer, offering a more effective treatment option for patients. The drug, daraxonrasib, targets a mutated protein responsible for tumor growth in over 90% of pancreatic cancer cases. In clinical trials involving 500 patients, those taking the new medication experienced nearly double the survival time compared to those receiving traditional chemotherapy. The approval comes as pancreatic cancer remains one of the deadliest cancers, with an estimated 67,000 new cases expected this year in the U.S. and a five-year survival rate of just 13%.
AI summary · Source: Telemundo McAllen (KTLM) →
